R
Robert L. Grubb
Researcher at Medical University of South Carolina
Publications - 25
Citations - 5174
Robert L. Grubb is an academic researcher from Medical University of South Carolina. The author has contributed to research in topics: Prostate cancer & Prostate cancer screening. The author has an hindex of 13, co-authored 25 publications receiving 4851 citations. Previous affiliations of Robert L. Grubb include Washington University in St. Louis & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Gerald L. Andriole,E. David Crawford,Robert L. Grubb,Saundra S. Buys,David Chia,Timothy R. Church,Mona N. Fouad,Edward P. Gelmann,Paul A. Kvale,Douglas J. Reding,Joel L. Weissfeld,Lance A. Yokochi,Jonathan D. Clapp,Joshua M. Rathmell,Thomas L. Riley,Richard B. Hayes,Barnett S. Kramer,Anthony B. Miller,Paul F. Pinsky,Philip C. Prorok,John K. Gohagan,Christine D. Berg +21 more
TL;DR: After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.
Journal ArticleDOI
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
Gerald L. Andriole,E. David Crawford,Robert L. Grubb,Saundra S. Buys,David Chia,Timothy R. Church,Mona N. Fouad,Claudine Isaacs,Paul A. Kvale,Douglas J. Reding,Joel L. Weissfeld,Lance A. Yokochi,Barbara O'Brien,Lawrence R. Ragard,Jonathan D. Clapp,Joshua M. Rathmell,Thomas L. Riley,Ann W. Hsing,Grant Izmirlian,Paul F. Pinsky,Barnett S. Kramer,Barnett S. Kramer,Anthony B. Miller,John K. Gohagan,Philip C. Prorok +24 more
TL;DR: There was no evidence of a mortality benefit for organized annual screening in the PLCO trial compared with opportunistic screening, which forms part of usual care, and there was no apparent interaction with age, baseline comorbidity, or pretrial PSA testing.
Journal ArticleDOI
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome.
Christian P. Pavlovich,Robert L. Grubb,Kathleen Hurley,Gladys Glenn,Jorge R. Toro,Laura S. Schmidt,Carlos Torres-Cabala,Maria J. Merino,Berton Zbar,Peter L. Choyke,McClellan M. Walther,W. Marston Linehan +11 more
TL;DR: Patients with BHD are at risk for multiple renal tumors that are often malignant and can metastasize and should be radiographically screened for renal tumors at periodic intervals and best treated with nephron sparing surgical approaches.
Journal ArticleDOI
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer.
Robert L. Grubb,Michael E. Franks,Jorge R. Toro,Lindsay A. Middelton,Lynda Choyke,Sarah Fowler,Carlos Torres-Cabala,Gladys Glenn,Peter L. Choyke,Maria J. Merino,Berton Zbar,Peter A. Pinto,Ramaprasad Srinivasan,Jonathan A. Coleman,W. Marston Linehan +14 more
TL;DR: Renal tumors in patients with hereditary leiomyomatosis and renal cell cancer syndrome are significantly more aggressive than those in patientsWith other hereditary renal tumor syndromes, the observation of 3 cm or less renal tumor size is not recommended.
Journal ArticleDOI
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial
Gerald L. Andriole,David L. Levin,E. David Crawford,Edward P. Gelmann,Paul F. Pinsky,David Chia,Barnett S. Kramer,Douglas J. Reding,Timothy R. Church,Robert L. Grubb,Grant Izmirlian,Lawrence R. Ragard,Jonathan D. Clapp,Philip C. Prorok,John K. Gohagan +14 more
TL;DR: The PLCO trial is evaluating PSA- and DRE-based screening for prostate cancer in a clinically valid manner, and whether such screening will result in a reduction of prostate cancer mortality cannot be answered until the randomized comparison is completed.